Conclusions
Severe and moderate hepatic impairment significantly increased exposure of naloxone and to a lesser extent of buprenorphine. Therefore, buprenorphine/naloxone combination products should generally be avoided in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone [Registered at ClinicalTrials.gov as NCT01846455] (Source: Clinical Pharmacokinetics)

Conclusions
Severe and moderate hepatic impairment significantly increased exposure of naloxone and to a lesser extent of buprenorphine. Therefore, buprenorphine/naloxone combination products should generally be avoided in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone [Registered at ClinicalTrials.gov as NCT01846455] (Source: Clinical Pharmacokinetics)

CONCLUSIONS: Evaluating prescription opioid-dependent patients after 2 weeks of buprenorphine-naloxone treatment may help determine the likelihood of successful outcome at completion of the current treatment regimen.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00316277.
PMID: 25562462 [PubMed – as supplied by publisher] (Source: Journal of Clinical Psychiatry)

CONCLUSIONS: Evaluating prescription opioid-dependent patients after 2 weeks of buprenorphine-naloxone treatment may help determine the likelihood of successful outcome at completion of the current treatment regimen.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00316277.
PMID: 25562462 [PubMed – as supplied by publisher] (Source: Journal of Clinical Psychiatry)

CONCLUSION:: In a cohort of pregnant patients treated with either methadone or buprenorphine and naloxone in pregnancy, newborns exposed to maternal buprenorphine and naloxone had less frequent neonatal abstinence syndrome. Additionally, neonates exposed to buprenorphine and naloxone had shorter overall hospitalization lengths. LEVEL OF EVIDENCE:: II.
PMID: 25569005 [PubMed – as supplied by publisher] (Source: Obstetrics and Gynecology)

CONCLUSIONS: The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States. (Am J Addict 2015;24:24-29).
PMID: 25823632 [PubMed – in process] (Source: The American Journal on Addictions)

CONCLUSIONS: In the United States opioid use and related unintentional lethal overdoses continue to rise, particularly in rural areas. Increasing access to office-based treatment of opioid use disorder-particularly in rural America-is a promising strategy to address rising rates of opioid use disorder and unintentional lethal overdoses.
PMID: 25583888 [PubMed – in process] (Source: Annals of Family Medicine)

One of the top outpatient Suboxone detox centers, Complete Care Medical Center, is now offering same week appointments with licensed specialists. The Center offers multiple licensed Suboxone doctors…(PRWeb December 28, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctor/fort-lauderdale-fl/prweb12416438.htm (Source: PRWeb: Medical Pharmaceuticals)

One of the top outpatient Suboxone detox centers, Complete Care Medical Center, is now offering same week appointments with licensed specialists. The Center offers multiple licensed Suboxone doctors…(PRWeb December 28, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctor/fort-lauderdale-fl/prweb12416438.htm (Source: PRWeb: Medical Pharmaceuticals)

Updated Date: Dec 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))